Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation

Int J Mol Sci. 2020 Dec 1;21(23):9165. doi: 10.3390/ijms21239165.

Abstract

The gastrointestinal (GI) mucosa is among the most complex systems in the body. It has a diverse commensal microbiome challenged continuously by food and microbial components while delivering essential nutrients and defending against pathogens. For these reasons, regulatory cells and receptors are likely to play a central role in maintaining the gut mucosal homeostasis. Recent lessons from cancer immunotherapy point out the critical role of the B7 negative co-stimulator PD-L1 in mucosal homeostasis. In this review, we summarize the current knowledge supporting the critical role of PD-L1 in gastrointestinal mucosal tolerance and how abnormalities in its expression and signaling contribute to gut inflammation and cancers. Abnormal expression of PD-L1 and/or the PD-1/PD-L1 signaling pathways have been observed in the pathology of the GI tract. We also discuss the current gap in our knowledge with regards to PD-L1 signaling in the GI tract under homeostasis and pathology. Finally, we summarize the current understanding of how this pathway is currently targeted to develop novel therapeutic approaches.

Keywords: PD-L1; gastrointestinal inflammation; homeostasis; inflammatory bowel disease.

Publication types

  • Review

MeSH terms

  • Animals
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / immunology
  • B7-H1 Antigen / metabolism*
  • Biomarkers
  • Disease Progression
  • Disease Susceptibility
  • Fibrosis
  • Gastrointestinal Diseases / etiology
  • Gastrointestinal Diseases / metabolism
  • Gastrointestinal Diseases / pathology
  • Homeostasis
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immune Tolerance* / genetics
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / etiology*
  • Inflammatory Bowel Diseases / metabolism*
  • Inflammatory Bowel Diseases / therapy
  • Intestinal Mucosa / immunology*
  • Intestinal Mucosa / metabolism*
  • Molecular Targeted Therapy

Substances

  • B7-H1 Antigen
  • Biomarkers
  • CD274 protein, human
  • Immune Checkpoint Inhibitors